Relatlimab and nivolumab in the treatment of melanoma
Authors listLewis Au James Larkin Samra Turajlic
Combined LAG-3 and PD-1 blockade is an emerging strategy for the treatment of melanoma. Tawbi et al. and Amaria et al. report in The New England Journal of Medicine and Nature respectively on two clinical trials evaluating relatlimab and nivolumab as front-line treatment for metastatic, and resectable, high-risk, node-positive melanoma.
Issue number 26
Full text links
Publisher website (DOI) 10.1016/j.cell.2022.12.003
Europe PubMed Central 36563660
Type of publication